GuidelineJournal of the American Academy of Dermatology2014
Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.
Guideline in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 285 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
285 citing papers in PubMed, 15 syntheses or guidelines pooled it, 861 citations in OpenAlex.
- Visualization of childhood allergic diseases based on VOSviewer and CiteSpace.Frontiers in medicine · 2025Pooled it
- Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.Dermatology (Basel, Switzerland) · 2024Guideline
- Efficacy of dupilumab plus topical corticosteroids in children with atopic dermatitis: A meta-analysis of randomized controlled trials.Immunity, inflammation and disease · 2024Pooled it
- Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.Frontiers in immunology · 2024Pooled it
- Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.Acta dermato-venereologica · 2022Pooled it
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.JAMA dermatology · 2022Pooled it
- Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.Dermatology (Basel, Switzerland) · 2022Pooled it
- Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.Frontiers in medicine · 2022Pooled it
- Clinical Efficacy of Integrated Traditional Chinese and Western Medicine in the Treatment of Eczema: A Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Phototherapy for atopic eczema.The Cochrane database of systematic reviews · 2021Pooled it
- Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Pooled it
- Systemic treatments for eczema: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.JAMA dermatology · 2020Pooled it
- Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).The British journal of dermatology · 2020Pooled it
- Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.Advances in therapy · 2026Trial
- Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.BMC medicine · 2026Trial
- Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.Frontiers in immunology · 2025Trial
- Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Trial
- Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial.Archives of dermatological research · 2024Trial
225 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 17 institutions in 4 countries.
Funding
Abstract
Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in atopic dermatitis management and care, providing recommendations based on the available evidence. In this third of 4 sections, treatment of atopic dermatitis with phototherapy and systemic immunomodulators, antimicrobials, and antihistamines is reviewed, including indications for use and the risk-benefit profile of each treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.